



REPORT

GF TADs SGE LSD 1st Teleconference on Lumpy Skin Disease (LSD) vaccine procurement in 2017

Thursday, 23 February 2017, 10:00 CET (Brussels time).

PARTICIPATING COUNTRIES

(See ANNEX attached hereto -Excel File)

Updates were provided on the estimated number of vaccine doses needed, state of play of national procurement, doses purchased already and estimated to be purchased as well as the estimated date of start of vaccination campaign for 2017

EUROPEAN COMMISSION (EC)

EU LSD vaccine bank

- Current capacity: 150.000 doses in stock + 350.000 doses available within relatively short time upon request.
- New tender to be launched early March for 2,3 million doses (estimated time of purchase: May 2017). Terms of Reference (TORs) will be publicly available to all countries.

EU Support for LSD vaccination in 2017 (EU Member States + non-EU Member Countries in South East Europe)

1. Reimbursement for the cost of vaccines purchased by national funds.

(preferable option, payment within 2-3 months from submission of claim)

- Reimbursement for the cost of vaccines that were bought and used (upon presentation of the relevant evidence/report) at a rate not higher than 1,1 EURO per dose.
- Additional documentation may be requested in advance (e.g. vaccination programme for 2017). Advance payment not an option for this year.
- Only vaccine costs to be covered, not cost of vaccination.
- EC ceiling for reimbursement per vaccine dose equal for all countries (1,1 EURO), independent of price of national purchase.
- EC reimbursement applies also to vaccines purchased and used from the stock of other countries (e.g. vaccines that may be bought from Hungary for use in a country implementing vaccination, e.g. by Greece)

2. Cost-free donations from the EU LSD vaccine bank.

(less preferable option at this stage, the EU LSD vaccine bank has to maintain a minimum strategic stock in place for emergency needs)

It may be used to provide small quantities of vaccines that are necessary for some countries, to ensure full vaccine coverage of all cattle before summer, e.g. to vaccinate their new-born calves in the period between now and the completion of their national vaccine purchase.

CLOSING REMARKS – FUTURE STEPS

- Unless a 2nd GF-TADs SGE LSD or teleconference is organised in the meantime, next meeting of the GF TADs SGE LSD should be expected in the margin of the OIE 2017 General Session (May 2017).
- Greece to investigate the possibility to buy the LSD vaccines in stock from Hungary.
- Country requests for grants from the EU LSD vaccine bank can be considered at this stage only for the quantities that are necessary to cover needs from now until the summer to ensure full vaccine coverage of all cattle .
- Detailed information on the procedures of EC reimbursement of LSD vaccines in 2017 to follow in due time.

List of participants

Country /organisation	Name
GF TADs Chair	Bernard Van Goethem
OIE / GF TADs Secretary	Nadège Leboucq
EC	Francisco Reviriego-Gordejo, Christophe Bertrand, Dimitrios Dilaveris
FAO	Mr Daniel Beltran Alcrudo, Eran Raizman
Albania	Ledi PITE
Austria	U. Herzog
Bosnia and Herzegovina	Ljubomir Kalaba, Zorana Mehmedbašić Devedžić
Croatia	Nikša Barišić
Greece	Chrysoula Dile, Sotiria-Eleni Antoniou
Hungary	Zsófia Szepesiné Kókány
Kosovo	Fillojete Rrustemaj
Montenegro	Vesna Dakovic ,Drago Marojevic
Romania	Grigore Marius
Serbia	Budimir Plavsic, Boban Djuric
Slovenia	Breda Hrovatin, Jedrt M. Wernig, Urska Galjot
The former Yugoslav Republic of Macedonia	Blagojcho Tabakovski
Ukraine	Olga Shevchenko, Olena Kuriata, Oleksii Klymenok, Andrii Pavlenko, Olena Stryga

-//-

